1. Search Result
Search Result
Isoforms Recommended: ADAM17
Results for "

ADAM-17

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

5

Peptides

2

Natural
Products

2

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10174A

    Fluorescent Dye MMP Others
    ADAM-17 Substrate is a fluorescent substrate of ADAM .
    ADAM-17 Substrate TFA
  • HY-120852
    JG26
    1 Publications Verification

    MMP Cancer
    JG26 is an ADAM17 inhibitor, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM for ADAM8, ADAM17, ADAM10 and MMP-12, respectively .
    JG26
  • HY-110397
    KP-457
    3 Publications Verification

    MMP Cardiovascular Disease
    KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.
    KP-457
  • HY-123931
    ZLDI-8
    1 Publications Verification

    Notch Phosphatase Apoptosis Cancer
    ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM .
    ZLDI-8
  • HY-115670
    GW280264X
    3 Publications Verification

    MMP Inflammation/Immunology Cancer
    GW280264X is the mixed ADAM10/TACE (ADAM17) metalloproteinases inhibitor. GW280264X potently blocks TACE (ADAM17) and ADAM10 with IC50s of 8.0 nM and 11.5 nM, respectively . ADAM10 and 17 modulate the immunogenicity of glioblastoma-initiating cells .
    GW280264X
  • HY-P10174

    Fluorescent Dye MMP Others
    ADAM-17 Substrate is a fluorescent substrate of ADAM .
    ADAM-17 Substrate
  • HY-RS00273

    Small Interfering RNA (siRNA) MMP Others

    Adam17 Rat Pre-designed siRNA Set A contains three designed siRNAs for Adam17 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Adam17 Rat Pre-designed siRNA Set A
    Adam17 Rat Pre-designed siRNA Set A
  • HY-RS00272

    Small Interfering RNA (siRNA) MMP Others

    Adam17 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Adam17 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Adam17 Mouse Pre-designed siRNA Set A
    Adam17 Mouse Pre-designed siRNA Set A
  • HY-RS00271

    Small Interfering RNA (siRNA) MMP Others

    ADAM17 Human Pre-designed siRNA Set A contains three designed siRNAs for ADAM17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ADAM17 Human Pre-designed siRNA Set A
    ADAM17 Human Pre-designed siRNA Set A
  • HY-110397G

    MMP Cardiovascular Disease
    KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC50s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively .
    KP-457 (GMP)
  • HY-16657
    TAPI-1
    Maximum Cited Publications
    9 Publications Verification

    MMP Inflammation/Immunology Cancer
    TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins . TAPI-1 is also a metalloproteinase (MMP) inhibitor .
    TAPI-1
  • HY-12636

    MMP Apoptosis Cancer
    INCB3619 is a selective and orally active ADAM inhibitor with IC50 of 22 nM and 14 nM for ADAM10 and ADAM17, respectively. INCB3619 has anti-tumor activity .
    INCB3619
  • HY-118694

    TNF Receptor MMP Bacterial Infection Cancer
    TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing .
    TAPI-0
  • HY-19667

    DPC 333

    TNF Receptor Inflammation/Immunology
    BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .
    BMS-561392
  • HY-16657A

    MMP mAChR Neurological Disease Inflammation/Immunology Cancer
    (S,S)-TAPI-1 is an isomer of TAPI-1. TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (MMP) inhibitor .
    (S,S)-TAPI-1
  • HY-172394

    HDAC ADAMTS Cancer
    ZSNI-21 is a dual inhibitor of ADAM17 and HDAC2. ZSNI-21 effectively inhibits the proliferation of Bel-7402 cells and demonstrates significant anti-metastatic capabilities against HCC-LM3 cells. ZSNI-21 is promising for research of hepatocellular carcinoma (HCC) .
    ZSNI-21
  • HY-19667A
    BMS-561392 formate
    1 Publications Verification

    DPC 333 formate

    TNF Receptor Inflammation/Immunology
    BMS-561392 formate is the formate form of BMS-561392 (HY-19667). BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .
    BMS-561392 formate
  • HY-10293

    INCB007839; INCB7839

    MMP Cancer
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al .
    Aderbasib
  • HY-P3722

    Fluorescent Dye MMP Others
    Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescent peptide and as one of fluorescent substrates of TNF-α converting enzyme (TACE; ADAM17), ADAM 9 and ADAM 10. Mca-PLAQAV-Dpa-RSSSR-NH2 is a substrate based on fluorescence resonance energy transfer, and its activity can be determined by the change of fluorescence intensity during pyrolysis .
    Mca-PLAQAV-Dpa-RSSSR-NH2
  • HY-P3722A

    Fluorescent Dye MMP Others
    Mca-PLAQAV-Dpa-RSSSR-NH2 is a fluorescent peptide and as one of fluorescent substrates of TNF-α converting enzyme (TACE): ADAM17, ADAM 9 and ADAM 10. Mca-PLAQAV-Dpa-RSSSR-NH2 is a substrate based on fluorescence resonance energy transfer, and its activity can be determined by the change of fluorescence intensity during pyrolysis .
    Mca-PLAQAV-Dpa-RSSSR-NH2 TFA
  • HY-101448

    WAY-171318

    MMP Apoptosis Interleukin Related TNF Receptor Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-αIL-1βIL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
    TMI-1
  • HY-101984
    N6,N6-Dimethyladenosine
    2 Publications Verification

    Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV Infection Cancer
    N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines .
    N6,N6-Dimethyladenosine
  • HY-165060

    (±)2-14,15-EG

    DNA/RNA Synthesis Metabolic Disease
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol ((±)2-14,15-EG) is a novel CYP450 metabolite of 2-Arachidonoyl glycerol (2-AG) in the kidney. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol is a potent mitogen for renal epithelial cells, increasing DNA synthesis in LLCPKcl4 cells. (±)2-(14,15-Epoxyeicosatrienoyl) glycerol activates the metalloprotease ADAM17, which cleaves proTGF-α and releases TGF-α as a ligand that initiates the EGFR-ERK signalling pathway .
    (±)2-(14,15-Epoxyeicosatrienoyl) glycerol
  • HY-101984R

    Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV Infection Cancer
    N6,N6-Dimethyladenosine (Standard) is the analytical standard of N6,N6-Dimethyladenosine (HY-101984). This product is intended for research and analytical applications. N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines.
    N6,N6-Dimethyladenosine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: